Revolution Medicines’ experimental pill daraxonrasib has reportedly doubled survival in early trials for pancreatic cancer, sparking cautious optimism in the fight against one of the deadliest cancers. The drug targets the KRAS gene, which provides instructions for the K-Ras protein—a key switch controlling cell division, growth, and death. Mutations in KRAS are common in pancreatic cancer and have long been considered ‘undruggable.’
Pancreatic cancer has a five-year survival rate of just 12%, according to the American Cancer Society, and few treatment advances have emerged in recent decades. The new oral therapy could represent a breakthrough if confirmed in larger studies. Early-phase trial results showed that daraxonrasib extended survival in patients with advanced pancreatic cancer compared to standard chemotherapy.
The development comes as the field of targeted cancer therapies accelerates. Other companies, including Calidi Biotherapeutics Inc. (NYSE American: CLDI), are also making progress with oncolytic virus therapies, which use viruses to infect and destroy cancer cells. These diverse approaches highlight a growing momentum in precision oncology.
Daraxonrasib belongs to a class of KRAS inhibitors that have recently shown success in lung cancer, but pancreatic cancer has proven more challenging due to the dense tumor microenvironment and genetic complexity. The drug works by binding to a specific mutant form of KRAS (G12D), which is present in about 40% of pancreatic cancers.
Analysts caution that early trial results, while promising, require confirmation in larger, randomized trials. Side effects have included fatigue, nausea, and liver enzyme elevations, but were generally manageable. If approved, daraxonrasib could become a new standard of care for a subset of pancreatic cancer patients.
The news was shared via TinyGems, a communications platform focusing on innovative small-cap and mid-cap companies. TinyGems is part of the Dynamic Brand Portfolio @IBN and provides services including press release distribution and social media amplification.
While the road to approval remains long, the prospect of a pill that can be taken at home, rather than intravenous chemotherapy, represents a significant quality-of-life improvement for patients. The findings add to a wave of optimism that pancreatic cancer may finally be yielding to modern molecular targeting.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is New Pill Daraxonrasib Shows Promise in Doubling Survival for Pancreatic Cancer Patients.